Pinsent Masons in collaboration with the Industry Forum hosts a live online discussion looking at whether the current patent system is still fit for purpose for incentivising the development of therapeutics, the current challenges faced by the industry and whether we need to look to alternative models and systems to realise the full potential of innovation.
The first event of our 'Incentivising Life Sciences Innovation' series is a discussion with Daniel Zeichner MP, All-Party Parliamentary Group for Life Sciences and Chair of the APPG, David Rosenberg, expert on IP policy development for the pharmaceutical industry (ex-GSK) and members of Pinsent Masons' European life sciences team.
Ex VP IP Policy at GSK
MP at All-Party Parliamentary Group for Life Sciences and Chair of the APPG
CHair/CEO at The Industry Forum